	US 12,083,163 B2
	Isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases
Carole Guillonneau, Nantes (FR); Ignacio Anegon, Nantes (FR); and Séverine Bezie, Nantes (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); and UNIVERSITE DE NANTES, Nantes (FR)
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); and UNIVERSITÉ DE NANTES, Nantes (FR)
Filed on Jul. 9, 2021, as Appl. No. 17/371,646.
Application 17/371,646 is a division of application No. 16/174,837, filed on Oct. 30, 2018, granted, now 11,090,362.
Application 16/174,837 is a division of application No. 15/326,515, granted, now 10,155,025, issued on Dec. 18, 2018, previously published as PCT/EP2015/066407, filed on Jul. 17, 2015.
Claims priority of application No. 14306165 (EP), filed on Jul. 17, 2014; and application No. 15305935 (EP), filed on Jun. 16, 2015.
Prior Publication US 2021/0401940 A1, Dec. 30, 2021
Int. Cl. A61K 38/20 (2006.01); A61K 31/436 (2006.01); A61K 45/06 (2006.01); G01N 33/564 (2006.01); G01N 33/68 (2006.01)

CPC A61K 38/20 (2013.01) [A61K 31/436 (2013.01); A61K 45/06 (2013.01); G01N 33/564 (2013.01); G01N 33/6893 (2013.01); G01N 2333/54 (2013.01); G01N 2800/245 (2013.01); G01N 2800/50 (2013.01)]

11 Claims

1. A method of treating an autoimmune disease, wherein said autoimmune disease involves CD4+ and/or CD8+ T cells, an unwanted immune response against a therapeutic protein or an allergy in a subject in need thereof, comprising administering an effective amount of interleukin-34 (IL-34) to said subject.